Sunitinib malate in solitary fibrous tumor (SFT)

S. Stacchiotti, T. Negri, M. Libertini, E. Palassini, A. Marrari, B. De Troia, A. Gronchi, A. P. Dei Tos, C. Morosi, A. Messina, S. Pilotti, P. G. Casali

Research output: Contribution to journalArticlepeer-review


Background: To report on sunitinib activity in a retrospective series of 35 solitary fibrous tumor (SFT) treated at a single institution. Patients and methods: From April 2008, 35 patients with progressive advanced SFT (male/female: 20/15; mean age: 58 years; meningeal/extrameningeal: 6/29; locally advanced/metastatic: 15/20; prior chemotherapy: 25) were treated, on an individual use basis, with continuous-dosing sunitinib 37.5 mg/day. Platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 2 (VEGFR2) status were assessed by immunohistochemistry and, in a subgroup of patients, by real time PCR. Results: Thirty-one patients were assessable for response by RECIST (one early death; three early interruptions). Best responses were 2 partial response (PR), 16 stable disease, 13 progressive disease. A

Original languageEnglish
Article numbermds143
Pages (from-to)3171-3179
Number of pages9
JournalAnnals of Oncology
Issue number12
Publication statusPublished - Dec 2012


  • Chemotherapy
  • Hemangioperycitoma
  • Sarcoma
  • Solitary fibrous tumor
  • Sunitinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Hematology


Dive into the research topics of 'Sunitinib malate in solitary fibrous tumor (SFT)'. Together they form a unique fingerprint.

Cite this